A Pan-Cancer Analysis of the Oncogenic Role of Transcription Factor 3 in Human Tumors

Background: It has been proposed that transcription factor 3 (TCF3) is involved in the development of lymphocytic malignancies. However, no systematic pan cancer analysis has been conducted, and the role of TCF3 in human cancer prognosis and immunology is still largely unknown. Methods: Here, we use TCGA (cancer genome map), GEO (gene expression synthesis) dataset, human protein map (HPA) and some bioinformatics tools to explore the role of TCF3 in 33 tumor types. Results: We evaluated the expression of TCF3 in tumors. We found that for tumors with high expression of TCF3, such as Adrenocortical carcinoma, Kidney renal clear cell carcinoma, Liver hepatocellular carcinoma, Mesotellioma, Prostate adenocarcinoma and Sarcoma, the overexpression of TCF3 usually indicates poor OS. We also evaluated the mutation load of TCF3 in cancer and TCF3 related survival rate of cancer patients, and compared the phosphorylation of TCF3 in primary tumors and normal tissues. In conclusion, from the comprehensive pan cancer analysis of TCF3, we found that there was a significant statistical correlation between the expression of TCF3 and the clinical prognosis, protein phosphorylation, immune cell infiltration, pan cancer immune subtypes and molecular subtypes, tumor mutation burden or microsatellite instability of a variety of human cancers. Conclusions: TCF3 may be a potential prognostic and immune biomarker of pan cancer. In addition, TCF3 may be a new target for tumor immunotherapy.